Carregant...
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer immune responses that eradicate malignant cells while generating immunological memory to prevent disease relapse. Over the past few years, immunomodulatory monoclonal antibodies (mAbs) that block co-inhibitory rece...
Guardat en:
| Publicat a: | Oncoimmunology |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5706611/ https://ncbi.nlm.nih.gov/pubmed/29209572 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1371896 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|